Is Cancer the Next Breakthrough for Moderna After COVID-19? Sundeep Ganoria 22 hrs ago MRNA's cancer therapy scores a first phase III win, fueling hopes its mRNA platform can drive growth beyond COVID-19 vaccines.
Pfizer Rises Almost 7% Post Q2 Results: How to Play the Stock Kinjel Shah Aug 10, 2026 Pfizer's Q2 beat and raised 2026 revenue outlook signal progress, but declining COVID sales and patent losses challenge its growth path.
PFE Q2 Earnings Top, 2026 Sales View Tweaked, COVID Forecast Cut Zacks Equity Research Aug 4, 2026 Pfizer beats Q2 earnings and revenue estimates, raises the low end of its 2026 sales outlook, but lowers expectations for COVID product revenues.
Pfizer Stock Ahead of Q2 Earnings: To Buy or Not to Buy? Kinjel Shah Jul 29, 2026 Pfizer heads into Q2 earnings with expectations for growth in key products, COVID headwinds, and guidance updates that could shape its outlook.
